Date Title Description PDF
27 Feb 2024 On P&L The Company releases the full year 2023 financial results presentation. Download
27 Feb 2024 About Corporate Governance The Company informs about the agreements adopted by the Board of Directors Download
08 Nov 2023 On P&L The Company releases the press release related to the first nine months of 2023 financial results Download
08 Nov 2023 On P&L The Company releases the first nine months 2023 financial results presentation Download
26 Jul 2023 On buy-back programmes The Company reports the commencement, effective as of today, 26 July 2023, of a share buyback program.   Download

Pages

Date Title Description PDF
11 Dec 2023 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 1 December and 8 December 2023 Download
01 Dec 2023 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 24 November and 30 November 2023 Download
24 Nov 2023 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 17 November and 23 November 2023 Download
17 Nov 2023 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 10 November and 16 November 2023 Download
10 Nov 2023 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 3 November and 9 November 2023 Download

Pages

Date Title Description PDF
08 Jan 2018 Contratos de liquidez y contrapartida Liquidity contract: transactions conducted in the fourth quarter of 2017 Download
21 Dec 2017 Préstamos, créditos y avales ROVI and the EIB agree to sign a loan to boost research into drug administration and prolonged-release technologies Download
08 Nov 2017 Información sobre Resultados ROVI releases the press release related to the nine-month period ended 30 September 2017 results Download
08 Nov 2017 Información sobre Resultados ROVI releases the presentation related to the nine-month period ended 30 September 2017 results. Download
24 Oct 2017 Otros sobre negocio y situación financiera The Company releases the presentation related to the update of its Phase III-Prima 3 Risperidone ISM® project. Download

Pages